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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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Introduction
Epilepsy is one of the most common chronic neurological disorders requiring prolonged treatments and drugs. 
According to The World Health Organization (WHO), epilepsy is one of those serious brain disorders that affect not only 
the individual but has a deep impact on the family and society in general. Approximately 50 million people are affected 
with epilepsy around the world36, though proper epidemiological studies do not exist for Pakistan it is estimated that 
the prevalence of epilepsy is 9.99/1000. Highest prevalence is seen in people younger than 30 years of age, i.e. about 
2 million people and 1/10th of the world burden of epilepsy is in Pakistan! The guidelines available in developed 
countries are gauged in a setting where epilepsy care is provided by epileptologists/neurologists. In Pakistan the 
scenario is different, there is only one neurologist for 1.4 million (14lac) population contrast to US where one 
neurologist for 26 thousand people 29. So there is a desperate need to adapt to alternate guidelines with strategies 
to provide epilepsy management at a primary care level and to standardize epilepsy care on a National level.
Methods
To form these guidelines we reviewed and adopted from many different available guidelines mainly 
1. Local adaptations of the WHO recommendations4
2. Modification of the ILAE treatment guide lines: evidence based analysis of AEDs 200611
3. Updated ILAE evidence review of AEDs special report 201312 
4. Existing guidelines in other low income countries13-15 
5. NICE, AAN, AES recommendations.17-21
Results
These guidelines consist of 
1. The universally ILAE accepted  definition and classification of epilepsy and Epileptic syndromes with A step wise  
 approach to a patient with seizures and epilepsy in Pakistan.
2. Tables Selecting the right drug with evidence based references keeping in mind the cost and availability in Pakistan.
3. AED selection in special populations e.g. women20, children17 and elderly
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
4. Status Epilepticus Protocol
5. Algorithms and tables for easy access
(Due to the limitation of space , points 3 and 4 will 
be published subsequently)
CONCLUSION
The primary scope of these guidelines is to provide a 
concise practical management plan which considers the 
role of AEDs especially their judicial useThese guidelines 
hope to provide the physicians treating epilepsy patients 
with a step wise cost effective approach to the patient 
with epilepsy. A separate guideline to classification and 
diagnosis is also available, and the guidelines in entirety 
are also available on line at the Pakistan Society of 
Neurology website.
Guidelines Introduction
Epilepsy is one of the most common chronic neurological 
disorders requiring prolonged treatments and drugs. It is 
a disorder that is widely misunderstood and carries a 
vicious stigma. Epilepsy comprises a vast group of 
disorders and syndromes with one common symptom, 
“The Seizure”. For the purpose of these guidelines we 
have integrated the International League Against 
Epilepsy (ILAE) definitions of seizures and epilepsy. There 
is a vast array of literature and guidelines that exist in 
developed countries for over a decade. These have been 
reviewed and compiled and modified to suit the Pakistani 
population and socioeconomic status. These guidelines 
hope to help improve medical decision making in 
Pakistan while treating the patient with epilepsy (PWE)
THE NEED FOR NATIONAL GUIDELINES FOR 
EPILEPSY IN PAKISTAN: 
Epilepsy has varied etiologies and affects all age 
groups, but the vast majority of cases are treatable with 
Anti Epileptic Drugs (AEDs) most of which are easily 
available. However knowledge about epilepsy and its 
care is extremely low. The majority of people with 
epilepsy (PWE) are treated inadequately or 
inappropriately. According to The World Health 
Organization ( WHO), epilepsy is one of those serious 
brain disorders that affect not only the individual but 
has a deep impact on the family and society in general. 
Approximately 50 million people are affected with 
epilepsy around the world,4 and this number will 
increase with the new definition. Though proper 
epidemiological studies do not exist for Pakistan it is 
estimated that the prevalence of epilepsy is 
9.99/1000. Highest prevalence is seen in people 
younger than 30 years of age5. That is: about 2 million 
people and 1/10th of the world burden of epilepsy is in 
Pakistan. The recent estimates of population of Pakistan 
exceed 180 million, whereas the total number of trained 
neurologists in Pakistan is estimated to be 135 (Pakistan 
Society of Neurology Directory 2013)5. Based on the 
available data, the estimated 2 million people suffering 
from epilepsy in Pakistan, makes it one neurologist 
available for every 15200 sufferers of epilepsy with only 
few trained in epilepsy. Despite efforts to create 
awareness there remains a wide treatment gap and 
misconception. The guidelines available in developed 
countries are gauged in a setting where epilepsy care is 
provided by epileptologists/ neurologists. In Pakistan it is 
a different scenario, there is only one neurologist for 1.4 
million population contrast to US where one neurologist 
for 26 thousand people4. So there is a desperate need to 
adapt to alternate guidelines with strategies to provide 
epilepsy management at a primary care level and to 
standardize epilepsy care on a National level. The 
primary care physicians in civil hospitals and 
dispensaries, and general practioners (GPs), form the 
crux of health care in Pakistan and therefore see most of 
the PWE. Unfortunately neurology rotation is not a 
mandatory in undergraduate training thus most lack the 
information and skill needed for proper epilepsy 
diagnosis and management. In 2011, WHO mental 
health Gap Action Programme (mhGAP) released 
evidence based epilepsy care guidelines for use in low 
and middle income countries4. These guidelines provide 
a crudePerforma that requires local adaptation for use 
within individual countries. The guidelines state “For 
effective implementation and sustainability, the sense 
of ownership and empowerment must be transferred 
from the global health authorities to the local people. 
Socio-cultural and financial barriers that impede the 
implementation of the guidelines should be identified 
and ameliorated.4
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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Factor Developed country Developing country like Pakistan
Gross National income > USD 3036 < USD 565
Access to Health care Primary care for all with  Limited to 
 established referral systems very basic
  primary 
  care 
Health care funding  National programs and private Often ill funded 
 insurance systems rely on donors or    
  volunteers. No 
  set system of 
  insurance
Cultural perception of seizures Biomedical model  Traditional medicine,  
  spiritual approach,  
  contagion belief 
  common
Common Epilepsy etiologies Ideopathic, neoplastic cerebrovacular Post infectious, 
  antenatal, 
  post traumatic
Socio-cultural attitudes towards At lease social presentation of neutrality Overt negative 
epilepsy  public perception, 
  stigmatization, and
  discrimination common
Treatment gap <20% 70-94% 
Table 1: Factors to consider while developing National guidelines.
ARIABLES AFFECTING SELECTION OF AEDS IN PAKISTAN 
Epidemiological studies of prevalence and incidence reviewedare problematic in Pakistan due to lack of proper data 
collection teams and resources. Data concerning seizure type, etiology, and severity of seizuresare contrasted with those 
from developed countries. Sociocultural aspects of epilepsy have been poorly studied, and yet are fundamental to 
effective medical management. Thus the principles and success of treatment in Pakistan may differ considerably from 
developed countries. The principles of drug therapy may not be understood by patients, and the supply of drugs is often 
erratic; and these are major reasons for poor compliance with treatment. Therapy need to be prioritized to cost 
effectiveness, requiring a cheaper drug eg.phenobarbital to be tried as first line contrary to international guidelines. 
Computations of treatment gap figures in three developing countries suggest that between 80-94% of patients with active 
epilepsy are not receiving anticonvulsant therapy, cost and cultural belief sare two of the main factors.
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
To form these guidelines we reviewed and adopted from 
many different available guidelines mainly.
 
1)   Local adaptations of the WHO recommendations (4)
2)   Modification of the ILAE treatment guidelines:  
     based analysis of AEDs 2006 (11)
3)   Updated ILAE evidence review of AEDs special 
     report 2013(12)
4)   Existing guidelines in other low income countries 
          (13’14’15’16)
5)   NICE guidelines,(17)
6)   AAN practice parameters, (18)
7)   AES recommendations.(19)
8)   A multitude of literature to support our selection 
     and recommendations (20-43) 
Management Guidelines:
QUESTIONS ADDRESSED 
Q1-Q3: AEDs Initiation of therapy/Mono therapy; 
Adjuvant therapy; Cessation of therapy
Q4-Q7: Women (fertility, contraception, conception, 
pregnancy, lactation, teratogenicity), Children, elderly 
differences
Q8-Q9: Status Epilepticus in Adults and children (protocols)
Q10-Q13: Access to medications, direct and indirect 
costs, co-morbid conditions, preventable causes
Q14-Q15: Alternate Therapies, diet. 
Q16: Epilepsy surgery.
Q17-Q19: Lifestyle, Career choices, Driving.
Q20-23: Epilepsy Diaries, lockets, keychain or bracelets, 
Help line. 
Monotherapy Guideline questions:
Q1-Q3: Patients (adults/elderly/children) with partial- 
onset seizures
Q4-Q5: Patients (adults/children) with generalized-
onset tonic-clonic seizures
Q6: Children with idiopathic localization-related 
epilepsies and syndromes (BECTS).
Q7-Q8: Children with idiopathic-generalized epilepsies 
(CAE, JME).
Q9: Special Issues related to Women.
Q10: Considerations in Elderly and Multiple handicapped
Questions 6-10 are discussed in the special population 
subset of these guidelines not published in this edition.
For Classification and Diagnosis guidelines see Appendix A 
MANAGEMENT OF EPILEPSY
Non-pharmacological Management: 
Once diagnosis is made patient and family members 
need to be counselled empathically. Since the disease 
still carries a strong stigma, confidentiality needs to be 
maintained at all steps, and the condition should be 
discussed with any family member with consent of the 
PWE.
•    Establish the diagnosis 
•    Education/ counselling
•    Address psychosocial issues
•    Lifestyle modifications
Patients need counselling regarding the 
•    Disease
•    Drognosis 
•    Need for medication
•    Compliance
•    Life style
Life style modification includes 
•    Adequate sleep - early to bed early to rise
•    Change in job e.g. occupation, driving, swimmers, 
     boxers, airplane pilots etc.
•    Avoidance of alcohol, stimulants, energy drinks, 
     gutka, JM, etc.
•    Stress reduction — specific techniques, Yoga, 
     meditation, early morning walks 
•    Adequate diet – high protein. Low carbohydrate, 
     Vit. D, B rich diet
•    Joining support groups
•    Avoid social isolation
Pharmacological treatment of epilepsy 
 
The mainstay of treatment for epilepsy is antiepileptic 
drugs (AEDs) taken daily to prevent the recurrence of 
epileptic seizures.  It is important that the treatment 
strategy and suitability of the AED is determined by the 
prescriber keeping the individual with epilepsy and 
thecarer informed before drug therapy is started. 
When to Start AEDs after first seizures 
Whether to treat first seizure is controversial studies show 
16-62% recur within 5 years, Relapse rate is reduced by 
antiepileptic drug treatment, and it is now recommended 
that since Neurological abnormalities, abnormal imaging, 
abnormal EEG or family history increase relapse risk these 
patients should be treated after first seizure. 
(Table 4)
AED should be selected according to suitability of the 
patient, type of epilepsy etc.
Table 3 shows factors determining suitability. 
 
Table 5
The diagnosis of epilepsy needs to be critically evaluated if 
events continue despite an optimal dose of a first line AED. 
Before combination therapy is considered, PWE should be 
given a trial of at least 2-3 appropriate monotherapy 
regimens, with caution during the transition.
General Recommendations:
1)   It is recommended that PWE should be treated 
     with a single AED (monotherapy).  If the initial 
     treatment is unsuccessful, then monotherapy 
     using another drug can be tried.  
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A person is considered to have epilepsy if they meet any of the following conditions:
At least two unprovoked (or reflex) seizures occurring greater than 24 hours apart.
One unprovoked (or reflex) seizure and a probability of further seizures similar to the general recurrence risk (at least 
60%) after two unprovoked seizures, occurring over the next 10 years.
Diagnosis of an epilepsy syndrome
2)   Caution is needed during the changeover period, 
     with the second drug titrated and the first drug 
     decreased gradually. 
3)   It is recommended that combination therapy 
     (adjunctive or ‘add-on’ therapy) should only be 
     considered when attempts at monotherapy with 
     AEDs have not resulted in seizure control. 
4)   If trials of combination therapy do not bring about 
     worth while benefits, Diagnosis should be revisited 
     and treatment should revert to the regimen with 
     best control providing efficacy in reducing seizures 
     and tolerability of side effects.  
5)   Refer to specialist for phase II evaluation and 
     Epilepsy surgery, classify and diagnose cause of 
     refractory epilepsy, epileptic or non-epileptic fits.
6)   If an AED has failed because of adverse effects or 
     continued seizures, a second drug should be 
     started (which may be an alternative first-line or 
     second-line drug) and built up to an adequate or 
     maximum tolerated dose and then the first drug 
     should be tapered off slowly.  
7)   If the second drug is unhelpful, either the first or 
     second drug may be tapered, depending on 
     relative efficacy, side effects and how well the 
     drugs are tolerated before starting another drug.
8)   It should be recognised that some PWEs (through 
     their families in some instances) may choose not 
     to take AED therapy following a full discussion of 
     risks and benefits. Reason should be sought and 
     addressed accordingly. Treatment should be 
     insisted upon if risk of recurrence is high as 
     described in table 3. 
9)   Treatment of a first unprovoked seizure reduces 
     the risk of recurrence in the short-term. 
     In children, treatment of a first unprovoked seizure 
     does not alter the long-term prognosis for seizure
     remission.
10) AED therapy should only be started once the 
     diagnosis of epilepsy is confirmed, except in 
     exceptional circumstances that require discussion 
     and agreement between the physician and the 
     PWE and/or carers as appropriate.   
11) Continuing AED therapy should be planned by the 
     physician. It should be part of the PWE agreed 
     treatment plan, which should include  details of 
     how  specific drug choices were made, drug 
     dosage, possible side effects, and action to take if 
     seizures persist.
12) When possible, choose which AED to offer on the 
     basis of the presenting epilepsy syndrome. If the 
     epilepsy syndrome is not clear at presentation, 
     base the decision on the presenting seizure 
     type(s). 
13) Consistent supply to the PWE of a particular
     manufacturer’s AED preparation is recommended. 
     Different preparations of some AEDs may vary in 
     bioavailability or pharmacokinetic profiles and care 
     needs to be taken to avoid reduced effect 
     orexcessive side effects. 
14) Where partial seizures are suspected prefer 
     sodium channel blockers as first line AEDs (see fig 1)
15) Where generalized seizure syndromes are susp- 
     ected consider broader spectrum AEDs (see fig 1)
16) Phenobarbitone is a broad spectrum efficacious 
     AED that is easily available in Pakistan at minimal 
     price, therefore should still be considered as first 
     line therapy where affordability is an issue as risk 
     of seizures outweigh the long term side effects. 
17) Phenobarbitone should be offered where 
     compliance due to cost is suspectected. 
18) If using carbamazepine, check LFTs.  
19) When prescribing sodium valproate to women nd 
     girls of present and future childbearing potential, 
     discuss the possible risk of malformation and 
     neurodevelopmental impairments in an unborn 
     child, particularly with high doses of this AED or 
     when using as part of  polytherapy. Vit B, folate 
     and calcium supplements should be added.
20) Lamotrigine should be administered with caution 
     and slow titration when given as monotherapy and 
     with even slower titration when combined with 
     inducers like valproate to avoid the risk of 
     idiosyncratic reactions like Steven Johnson’s 
     syndrome and toxic epidermolysis. All patients 
     should be counseled and warned to stop 
     medication and contact the physician immediately 
     if any rash appears. 
21) Levitiracetam should be given with neuropsychiat- 
     ric issues in mind and pyridoxine supplement.
22) Maintain a high level of vigilance for treatment 
     emergent adverse effects (for example, bone 
     health issues, blood dyscrasias, and neuropsychia- 
     tric issues)
23) If management is complicated, PWE should be 
     referred to specialist.   
24) The prescriber must ensure that the PWE and/or 
     carers as appropriate are fully informed about 
     treatment including action to be taken after a 
     missed dose or after a gastrointestinal upset.   
25) Regular blood test monitoring in PWE is not 
     recommended as routine, and should be done only 
     if clinically indicated or non-complance is suspect- 
     ed as below. 
     Examples of blood tests include: 
     Before surgery – clotting studies in those on 
     sodium valproate. For Patients on enzyme inducing 
     AEDs: CBC, Electrolytes, LFTs, Vit D levels, every 
     1-2 years. Test for serum amino acids, TSH and 
     urine for organic acids in all children with neonatal 
     non-infectious seizures and refractory seizures. 
26) Asymptomatic minor abnormalities in test results 
     are not necessarily an indication for changes in 
     medication.  
27) Every patient when stable should still have a 6 
     monthly follow-up to ensure compliance, and 
     review treatment plan and side effects.
28) For uncontrolled patients treatment should be 
     reviewed at regular intervals so PWE are not 
     maintained  for  long periods  on treatment that is 
     ineffective or  poorly tolerated,  when in doubt early 
     referral is more cost effective
29) Compliance can be optimized with the following:
-     Educating PWE and their families and/or carers in 
     the understanding of their condition and the 
     rationale of treatment 
-     Reducing the stigma associated with the condition 
-     Using simple medication regimens 
-     Positive relationships between healthcare 
     professionals PWE, and their family.
-     SMS bulk reminder module
 30) The risks and benefits of continuing or withdrawing 
     AED therapy should be discussed with PWE and/or 
     carers as appropriate, who have been seizure free 
     for at least 2 years At the end of the discussion, 
     they should understand their risk of seizure 
     recurrence  off treatment. This discussion should 
     take into account details of the PWE’s epilepy 
     syndrome, prognosis and life style. 
31) When AED treatment is being discontinued in PWE 
     who has been seizure free, it should be carried out 
     slowly (at least 2-3 months) and one drug should 
     be withdrawn at a time.
32) Particular care should be taken when withdrawing 
     benzodiazepines and barbiturates (may take up to 
     6 months or longer) because of the possibility of 
     drug- related withdrawal symptoms and/or seizure 
     recurrence.  
33) PWE and carer should be counseled whereby if 
     seizures recur  the last dose  reduction is reversed 
     and medical advice is sought.
 AED-specific variables Patient-specific variables Nation-specific variables
 Seizure type or Genetic background AED availability
 epilepsy  syndrome Age AED cost
 specific efficacy or  Gender Insurance coverage
 effectiveness Comedications Socio-cultural issues
 Dose-dependent  Comorbidities Compliance
 adverse effects Insurance coverage
 Idiosyncratic reactions Ability to swallow
 Chronic toxicities pills/tablets
 Teratogenicity
 Carcinogenicity
 Pharmacokinetics
 Interaction potential
 Formulations
Table 2: Factors affecting AED selection
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
To form these guidelines we reviewed and adopted from 
many different available guidelines mainly.
 
1)   Local adaptations of the WHO recommendations (4)
2)   Modification of the ILAE treatment guidelines:  
     based analysis of AEDs 2006 (11)
3)   Updated ILAE evidence review of AEDs special 
     report 2013(12)
4)   Existing guidelines in other low income countries 
          (13’14’15’16)
5)   NICE guidelines,(17)
6)   AAN practice parameters, (18)
7)   AES recommendations.(19)
8)   A multitude of literature to support our selection 
     and recommendations (20-43) 
Management Guidelines:
QUESTIONS ADDRESSED 
Q1-Q3: AEDs Initiation of therapy/Mono therapy; 
Adjuvant therapy; Cessation of therapy
Q4-Q7: Women (fertility, contraception, conception, 
pregnancy, lactation, teratogenicity), Children, elderly 
differences
Q8-Q9: Status Epilepticus in Adults and children (protocols)
Q10-Q13: Access to medications, direct and indirect 
costs, co-morbid conditions, preventable causes
Q14-Q15: Alternate Therapies, diet. 
Q16: Epilepsy surgery.
Q17-Q19: Lifestyle, Career choices, Driving.
Q20-23: Epilepsy Diaries, lockets, keychain or bracelets, 
Help line. 
Monotherapy Guideline questions:
Q1-Q3: Patients (adults/elderly/children) with partial- 
onset seizures
Q4-Q5: Patients (adults/children) with generalized-
onset tonic-clonic seizures
Q6: Children with idiopathic localization-related 
epilepsies and syndromes (BECTS).
Q7-Q8: Children with idiopathic-generalized epilepsies 
(CAE, JME).
Q9: Special Issues related to Women.
Q10: Considerations in Elderly and Multiple handicapped
Questions 6-10 are discussed in the special population 
subset of these guidelines not published in this edition.
For Classification and Diagnosis guidelines see Appendix A 
MANAGEMENT OF EPILEPSY
Non-pharmacological Management: 
Once diagnosis is made patient and family members 
need to be counselled empathically. Since the disease 
still carries a strong stigma, confidentiality needs to be 
maintained at all steps, and the condition should be 
discussed with any family member with consent of the 
PWE.
•    Establish the diagnosis 
•    Education/ counselling
•    Address psychosocial issues
•    Lifestyle modifications
Patients need counselling regarding the 
•    Disease
•    Drognosis 
•    Need for medication
•    Compliance
•    Life style
Life style modification includes 
•    Adequate sleep - early to bed early to rise
•    Change in job e.g. occupation, driving, swimmers, 
     boxers, airplane pilots etc.
•    Avoidance of alcohol, stimulants, energy drinks, 
     gutka, JM, etc.
•    Stress reduction — specific techniques, Yoga, 
     meditation, early morning walks 
•    Adequate diet – high protein. Low carbohydrate, 
     Vit. D, B rich diet
•    Joining support groups
•    Avoid social isolation
Pharmacological treatment of epilepsy 
 
The mainstay of treatment for epilepsy is antiepileptic 
drugs (AEDs) taken daily to prevent the recurrence of 
epileptic seizures.  It is important that the treatment 
strategy and suitability of the AED is determined by the 
prescriber keeping the individual with epilepsy and 
thecarer informed before drug therapy is started. 
When to Start AEDs after first seizures 
Whether to treat first seizure is controversial studies show 
16-62% recur within 5 years, Relapse rate is reduced by 
antiepileptic drug treatment, and it is now recommended 
that since Neurological abnormalities, abnormal imaging, 
abnormal EEG or family history increase relapse risk these 
patients should be treated after first seizure. 
(Table 4)
AED should be selected according to suitability of the 
patient, type of epilepsy etc.
Table 3 shows factors determining suitability. 
 
Table 5
The diagnosis of epilepsy needs to be critically evaluated if 
events continue despite an optimal dose of a first line AED. 
Before combination therapy is considered, PWE should be 
given a trial of at least 2-3 appropriate monotherapy 
regimens, with caution during the transition.
General Recommendations:
1)   It is recommended that PWE should be treated 
     with a single AED (monotherapy).  If the initial 
     treatment is unsuccessful, then monotherapy 
     using another drug can be tried.  
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Definitely:
With structural lesion like
Brain tumor, AVM, 
Infection, 
Without structural lesion:
h/o Epilepsy in sibling
EEG with definite pattern. 
Prior but remote sz prior 
neurological hist.
Todds post ictal paresis 
statusepilepticus at onset.
Possibly:
Unprovoked seizure
Probably not:
alcohol withdrawal
Drug abuse
Sz with acute illness
post impact seizure
A benign epilepsy 
syndrome.
Excessive sleep deprivation.
Factors determining AED suitability include: 
seizure type and/or epilepsy syndrome; 
childbearing potential; 
the presence of comorbidity;
individual and/or carer preferences; 
the presence of contraindications to the drug;
potential interactions with other drugs; 
potential adverse effects 
the licensed indication of the drug. 
Cost of AED 
Patients socio-economic status
Age 
Compliance 
AED availability
Adult lifestyle
2)   Caution is needed during the changeover period, 
     with the second drug titrated and the first drug 
     decreased gradually. 
3)   It is recommended that combination therapy 
     (adjunctive or ‘add-on’ therapy) should only be 
     considered when attempts at monotherapy with 
     AEDs have not resulted in seizure control. 
4)   If trials of combination therapy do not bring about 
     worth while benefits, Diagnosis should be revisited 
     and treatment should revert to the regimen with 
     best control providing efficacy in reducing seizures 
     and tolerability of side effects.  
5)   Refer to specialist for phase II evaluation and 
     Epilepsy surgery, classify and diagnose cause of 
     refractory epilepsy, epileptic or non-epileptic fits.
6)   If an AED has failed because of adverse effects or 
     continued seizures, a second drug should be 
     started (which may be an alternative first-line or 
     second-line drug) and built up to an adequate or 
     maximum tolerated dose and then the first drug 
     should be tapered off slowly.  
7)   If the second drug is unhelpful, either the first or 
     second drug may be tapered, depending on 
     relative efficacy, side effects and how well the 
     drugs are tolerated before starting another drug.
8)   It should be recognised that some PWEs (through 
     their families in some instances) may choose not 
     to take AED therapy following a full discussion of 
     risks and benefits. Reason should be sought and 
     addressed accordingly. Treatment should be 
     insisted upon if risk of recurrence is high as 
     described in table 3. 
9)   Treatment of a first unprovoked seizure reduces 
     the risk of recurrence in the short-term. 
     In children, treatment of a first unprovoked seizure 
     does not alter the long-term prognosis for seizure
     remission.
10) AED therapy should only be started once the 
     diagnosis of epilepsy is confirmed, except in 
     exceptional circumstances that require discussion 
     and agreement between the physician and the 
     PWE and/or carers as appropriate.   
11) Continuing AED therapy should be planned by the 
     physician. It should be part of the PWE agreed 
     treatment plan, which should include  details of 
     how  specific drug choices were made, drug 
     dosage, possible side effects, and action to take if 
     seizures persist.
12) When possible, choose which AED to offer on the 
     basis of the presenting epilepsy syndrome. If the 
     epilepsy syndrome is not clear at presentation, 
     base the decision on the presenting seizure 
     type(s). 
13) Consistent supply to the PWE of a particular
     manufacturer’s AED preparation is recommended. 
     Different preparations of some AEDs may vary in 
     bioavailability or pharmacokinetic profiles and care 
     needs to be taken to avoid reduced effect 
     orexcessive side effects. 
14) Where partial seizures are suspected prefer 
     sodium channel blockers as first line AEDs (see fig 1)
15) Where generalized seizure syndromes are susp- 
     ected consider broader spectrum AEDs (see fig 1)
16) Phenobarbitone is a broad spectrum efficacious 
     AED that is easily available in Pakistan at minimal 
     price, therefore should still be considered as first 
     line therapy where affordability is an issue as risk 
     of seizures outweigh the long term side effects. 
17) Phenobarbitone should be offered where 
     compliance due to cost is suspectected. 
18) If using carbamazepine, check LFTs.  
19) When prescribing sodium valproate to women nd 
     girls of present and future childbearing potential, 
     discuss the possible risk of malformation and 
     neurodevelopmental impairments in an unborn 
     child, particularly with high doses of this AED or 
     when using as part of  polytherapy. Vit B, folate 
     and calcium supplements should be added.
20) Lamotrigine should be administered with caution 
     and slow titration when given as monotherapy and 
     with even slower titration when combined with 
     inducers like valproate to avoid the risk of 
     idiosyncratic reactions like Steven Johnson’s 
     syndrome and toxic epidermolysis. All patients 
     should be counseled and warned to stop 
     medication and contact the physician immediately 
     if any rash appears. 
21) Levitiracetam should be given with neuropsychiat- 
     ric issues in mind and pyridoxine supplement.
22) Maintain a high level of vigilance for treatment 
     emergent adverse effects (for example, bone 
     health issues, blood dyscrasias, and neuropsychia- 
     tric issues)
23) If management is complicated, PWE should be 
     referred to specialist.   
24) The prescriber must ensure that the PWE and/or 
     carers as appropriate are fully informed about 
     treatment including action to be taken after a 
     missed dose or after a gastrointestinal upset.   
25) Regular blood test monitoring in PWE is not 
     recommended as routine, and should be done only 
     if clinically indicated or non-complance is suspect- 
     ed as below. 
     Examples of blood tests include: 
     Before surgery – clotting studies in those on 
     sodium valproate. For Patients on enzyme inducing 
     AEDs: CBC, Electrolytes, LFTs, Vit D levels, every 
     1-2 years. Test for serum amino acids, TSH and 
     urine for organic acids in all children with neonatal 
     non-infectious seizures and refractory seizures. 
26) Asymptomatic minor abnormalities in test results 
     are not necessarily an indication for changes in 
     medication.  
27) Every patient when stable should still have a 6 
     monthly follow-up to ensure compliance, and 
     review treatment plan and side effects.
28) For uncontrolled patients treatment should be 
     reviewed at regular intervals so PWE are not 
     maintained  for  long periods  on treatment that is 
     ineffective or  poorly tolerated,  when in doubt early 
     referral is more cost effective
29) Compliance can be optimized with the following:
-     Educating PWE and their families and/or carers in 
     the understanding of their condition and the 
     rationale of treatment 
-     Reducing the stigma associated with the condition 
-     Using simple medication regimens 
-     Positive relationships between healthcare 
     professionals PWE, and their family.
-     SMS bulk reminder module
 30) The risks and benefits of continuing or withdrawing 
     AED therapy should be discussed with PWE and/or 
     carers as appropriate, who have been seizure free 
     for at least 2 years At the end of the discussion, 
     they should understand their risk of seizure 
     recurrence  off treatment. This discussion should 
     take into account details of the PWE’s epilepy 
     syndrome, prognosis and life style. 
31) When AED treatment is being discontinued in PWE 
     who has been seizure free, it should be carried out 
     slowly (at least 2-3 months) and one drug should 
     be withdrawn at a time.
32) Particular care should be taken when withdrawing 
     benzodiazepines and barbiturates (may take up to 
     6 months or longer) because of the possibility of 
     drug- related withdrawal symptoms and/or seizure 
     recurrence.  
33) PWE and carer should be counseled whereby if 
     seizures recur  the last dose  reduction is reversed 
     and medical advice is sought.
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
To form these guidelines we reviewed and adopted from 
many different available guidelines mainly.
 
1)   Local adaptations of the WHO recommendations (4)
2)   Modification of the ILAE treatment guidelines:  
     based analysis of AEDs 2006 (11)
3)   Updated ILAE evidence review of AEDs special 
     report 2013(12)
4)   Existing guidelines in other low income countries 
          (13’14’15’16)
5)   NICE guidelines,(17)
6)   AAN practice parameters, (18)
7)   AES recommendations.(19)
8)   A multitude of literature to support our selection 
     and recommendations (20-43) 
Management Guidelines:
QUESTIONS ADDRESSED 
Q1-Q3: AEDs Initiation of therapy/Mono therapy; 
Adjuvant therapy; Cessation of therapy
Q4-Q7: Women (fertility, contraception, conception, 
pregnancy, lactation, teratogenicity), Children, elderly 
differences
Q8-Q9: Status Epilepticus in Adults and children (protocols)
Q10-Q13: Access to medications, direct and indirect 
costs, co-morbid conditions, preventable causes
Q14-Q15: Alternate Therapies, diet. 
Q16: Epilepsy surgery.
Q17-Q19: Lifestyle, Career choices, Driving.
Q20-23: Epilepsy Diaries, lockets, keychain or bracelets, 
Help line. 
Monotherapy Guideline questions:
Q1-Q3: Patients (adults/elderly/children) with partial- 
onset seizures
Q4-Q5: Patients (adults/children) with generalized-
onset tonic-clonic seizures
Q6: Children with idiopathic localization-related 
epilepsies and syndromes (BECTS).
Q7-Q8: Children with idiopathic-generalized epilepsies 
(CAE, JME).
Q9: Special Issues related to Women.
Q10: Considerations in Elderly and Multiple handicapped
Questions 6-10 are discussed in the special population 
subset of these guidelines not published in this edition.
For Classification and Diagnosis guidelines see Appendix A 
MANAGEMENT OF EPILEPSY
Non-pharmacological Management: 
Once diagnosis is made patient and family members 
need to be counselled empathically. Since the disease 
still carries a strong stigma, confidentiality needs to be 
maintained at all steps, and the condition should be 
discussed with any family member with consent of the 
PWE.
•    Establish the diagnosis 
•    Education/ counselling
•    Address psychosocial issues
•    Lifestyle modifications
Patients need counselling regarding the 
•    Disease
•    Drognosis 
•    Need for medication
•    Compliance
•    Life style
Life style modification includes 
•    Adequate sleep - early to bed early to rise
•    Change in job e.g. occupation, driving, swimmers, 
     boxers, airplane pilots etc.
•    Avoidance of alcohol, stimulants, energy drinks, 
     gutka, JM, etc.
•    Stress reduction — specific techniques, Yoga, 
     meditation, early morning walks 
•    Adequate diet – high protein. Low carbohydrate, 
     Vit. D, B rich diet
•    Joining support groups
•    Avoid social isolation
Pharmacological treatment of epilepsy 
 
The mainstay of treatment for epilepsy is antiepileptic 
drugs (AEDs) taken daily to prevent the recurrence of 
epileptic seizures.  It is important that the treatment 
strategy and suitability of the AED is determined by the 
prescriber keeping the individual with epilepsy and 
thecarer informed before drug therapy is started. 
When to Start AEDs after first seizures 
Whether to treat first seizure is controversial studies show 
16-62% recur within 5 years, Relapse rate is reduced by 
antiepileptic drug treatment, and it is now recommended 
that since Neurological abnormalities, abnormal imaging, 
abnormal EEG or family history increase relapse risk these 
patients should be treated after first seizure. 
(Table 4)
AED should be selected according to suitability of the 
patient, type of epilepsy etc.
Table 3 shows factors determining suitability. 
 
Table 5
The diagnosis of epilepsy needs to be critically evaluated if 
events continue despite an optimal dose of a first line AED. 
Before combination therapy is considered, PWE should be 
given a trial of at least 2-3 appropriate monotherapy 
regimens, with caution during the transition.
General Recommendations:
1)   It is recommended that PWE should be treated 
     with a single AED (monotherapy).  If the initial 
     treatment is unsuccessful, then monotherapy 
     using another drug can be tried.  
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2)   Caution is needed during the changeover period, 
     with the second drug titrated and the first drug 
     decreased gradually. 
3)   It is recommended that combination therapy 
     (adjunctive or ‘add-on’ therapy) should only be 
     considered when attempts at monotherapy with 
     AEDs have not resulted in seizure control. 
4)   If trials of combination therapy do not bring about 
     worth while benefits, Diagnosis should be revisited 
     and treatment should revert to the regimen with 
     best control providing efficacy in reducing seizures 
     and tolerability of side effects.  
5)   Refer to specialist for phase II evaluation and 
     Epilepsy surgery, classify and diagnose cause of 
     refractory epilepsy, epileptic or non-epileptic fits.
6)   If an AED has failed because of adverse effects or 
     continued seizures, a second drug should be 
     started (which may be an alternative first-line or 
     second-line drug) and built up to an adequate or 
     maximum tolerated dose and then the first drug 
     should be tapered off slowly.  
7)   If the second drug is unhelpful, either the first or 
     second drug may be tapered, depending on 
     relative efficacy, side effects and how well the 
     drugs are tolerated before starting another drug.
8)   It should be recognised that some PWEs (through 
     their families in some instances) may choose not 
     to take AED therapy following a full discussion of 
     risks and benefits. Reason should be sought and 
     addressed accordingly. Treatment should be 
     insisted upon if risk of recurrence is high as 
     described in table 3. 
9)   Treatment of a first unprovoked seizure reduces 
     the risk of recurrence in the short-term. 
     In children, treatment of a first unprovoked seizure 
     does not alter the long-term prognosis for seizure
     remission.
10) AED therapy should only be started once the 
     diagnosis of epilepsy is confirmed, except in 
     exceptional circumstances that require discussion 
     and agreement between the physician and the 
     PWE and/or carers as appropriate.   
11) Continuing AED therapy should be planned by the 
     physician. It should be part of the PWE agreed 
     treatment plan, which should include  details of 
     how  specific drug choices were made, drug 
     dosage, possible side effects, and action to take if 
     seizures persist.
12) When possible, choose which AED to offer on the 
     basis of the presenting epilepsy syndrome. If the 
     epilepsy syndrome is not clear at presentation, 
     base the decision on the presenting seizure 
     type(s). 
13) Consistent supply to the PWE of a particular
     manufacturer’s AED preparation is recommended. 
     Different preparations of some AEDs may vary in 
     bioavailability or pharmacokinetic profiles and care 
     needs to be taken to avoid reduced effect 
     orexcessive side effects. 
14) Where partial seizures are suspected prefer 
     sodium channel blockers as first line AEDs (see fig 1)
15) Where generalized seizure syndromes are susp- 
     ected consider broader spectrum AEDs (see fig 1)
16) Phenobarbitone is a broad spectrum efficacious 
     AED that is easily available in Pakistan at minimal 
     price, therefore should still be considered as first 
     line therapy where affordability is an issue as risk 
     of seizures outweigh the long term side effects. 
17) Phenobarbitone should be offered where 
     compliance due to cost is suspectected. 
18) If using carbamazepine, check LFTs.  
19) When prescribing sodium valproate to women nd 
     girls of present and future childbearing potential, 
     discuss the possible risk of malformation and 
     neurodevelopmental impairments in an unborn 
     child, particularly with high doses of this AED or 
     when using as part of  polytherapy. Vit B, folate 
     and calcium supplements should be added.
20) Lamotrigine should be administered with caution 
     and slow titration when given as monotherapy and 
     with even slower titration when combined with 
     inducers like valproate to avoid the risk of 
     idiosyncratic reactions like Steven Johnson’s 
     syndrome and toxic epidermolysis. All patients 
     should be counseled and warned to stop 
     medication and contact the physician immediately 
     if any rash appears. 
21) Levitiracetam should be given with neuropsychiat- 
     ric issues in mind and pyridoxine supplement.
22) Maintain a high level of vigilance for treatment 
     emergent adverse effects (for example, bone 
     health issues, blood dyscrasias, and neuropsychia- 
     tric issues)
23) If management is complicated, PWE should be 
     referred to specialist.   
24) The prescriber must ensure that the PWE and/or 
     carers as appropriate are fully informed about 
     treatment including action to be taken after a 
     missed dose or after a gastrointestinal upset.   
25) Regular blood test monitoring in PWE is not 
     recommended as routine, and should be done only 
     if clinically indicated or non-complance is suspect- 
     ed as below. 
     Examples of blood tests include: 
     Before surgery – clotting studies in those on 
     sodium valproate. For Patients on enzyme inducing 
     AEDs: CBC, Electrolytes, LFTs, Vit D levels, every 
     1-2 years. Test for serum amino acids, TSH and 
     urine for organic acids in all children with neonatal 
     non-infectious seizures and refractory seizures. 
26) Asymptomatic minor abnormalities in test results 
     are not necessarily an indication for changes in 
     medication.  
27) Every patient when stable should still have a 6 
     monthly follow-up to ensure compliance, and 
     review treatment plan and side effects.
28) For uncontrolled patients treatment should be 
     reviewed at regular intervals so PWE are not 
     maintained  for  long periods  on treatment that is 
     ineffective or  poorly tolerated,  when in doubt early 
     referral is more cost effective
29) Compliance can be optimized with the following:
-     Educating PWE and their families and/or carers in 
     the understanding of their condition and the 
     rationale of treatment 
-     Reducing the stigma associated with the condition 
-     Using simple medication regimens 
-     Positive relationships between healthcare 
     professionals PWE, and their family.
-     SMS bulk reminder module
 30) The risks and benefits of continuing or withdrawing 
     AED therapy should be discussed with PWE and/or 
     carers as appropriate, who have been seizure free 
     for at least 2 years At the end of the discussion, 
     they should understand their risk of seizure 
     recurrence  off treatment. This discussion should 
     take into account details of the PWE’s epilepy 
     syndrome, prognosis and life style. 
31) When AED treatment is being discontinued in PWE 
     who has been seizure free, it should be carried out 
     slowly (at least 2-3 months) and one drug should 
     be withdrawn at a time.
32) Particular care should be taken when withdrawing 
     benzodiazepines and barbiturates (may take up to 
     6 months or longer) because of the possibility of 
     drug- related withdrawal symptoms and/or seizure 
     recurrence.  
33) PWE and carer should be counseled whereby if 
     seizures recur  the last dose  reduction is reversed 
     and medical advice is sought.
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
To form these guidelines we reviewed and adopted from 
many different available guidelines mainly.
 
1)   Local adaptations of the WHO recommendations (4)
2)   Modification of the ILAE treatment guidelines:  
     based analysis of AEDs 2006 (11)
3)   Updated ILAE evidence review of AEDs special 
     report 2013(12)
4)   Existing guidelines in other low income countries 
          (13’14’15’16)
5)   NICE guidelines,(17)
6)   AAN practice parameters, (18)
7)   AES recommendations.(19)
8)   A multitude of literature to support our selection 
     and recommendations (20-43) 
Management Guidelines:
QUESTIONS ADDRESSED 
Q1-Q3: AEDs Initiation of therapy/Mono therapy; 
Adjuvant therapy; Cessation of therapy
Q4-Q7: Women (fertility, contraception, conception, 
pregnancy, lactation, teratogenicity), Children, elderly 
differences
Q8-Q9: Status Epilepticus in Adults and children (protocols)
Q10-Q13: Access to medications, direct and indirect 
costs, co-morbid conditions, preventable causes
Q14-Q15: Alternate Therapies, diet. 
Q16: Epilepsy surgery.
Q17-Q19: Lifestyle, Career choices, Driving.
Q20-23: Epilepsy Diaries, lockets, keychain or bracelets, 
Help line. 
Monotherapy Guideline questions:
Q1-Q3: Patients (adults/elderly/children) with partial- 
onset seizures
Q4-Q5: Patients (adults/children) with generalized-
onset tonic-clonic seizures
Q6: Children with idiopathic localization-related 
epilepsies and syndromes (BECTS).
Q7-Q8: Children with idiopathic-generalized epilepsies 
(CAE, JME).
Q9: Special Issues related to Women.
Q10: Considerations in Elderly and Multiple handicapped
Questions 6-10 are discussed in the special population 
subset of these guidelines not published in this edition.
For Classification and Diagnosis guidelines see Appendix A 
MANAGEMENT OF EPILEPSY
Non-pharmacological Management: 
Once diagnosis is made patient and family members 
need to be counselled empathically. Since the disease 
still carries a strong stigma, confidentiality needs to be 
maintained at all steps, and the condition should be 
discussed with any family member with consent of the 
PWE.
•    Establish the diagnosis 
•    Education/ counselling
•    Address psychosocial issues
•    Lifestyle modifications
Patients need counselling regarding the 
•    Disease
•    Drognosis 
•    Need for medication
•    Compliance
•    Life style
Life style modification includes 
•    Adequate sleep - early to bed early to rise
•    Change in job e.g. occupation, driving, swimmers, 
     boxers, airplane pilots etc.
•    Avoidance of alcohol, stimulants, energy drinks, 
     gutka, JM, etc.
•    Stress reduction — specific techniques, Yoga, 
     meditation, early morning walks 
•    Adequate diet – high protein. Low carbohydrate, 
     Vit. D, B rich diet
•    Joining support groups
•    Avoid social isolation
Pharmacological treatment of epilepsy 
 
The mainstay of treatment for epilepsy is antiepileptic 
drugs (AEDs) taken daily to prevent the recurrence of 
epileptic seizures.  It is important that the treatment 
strategy and suitability of the AED is determined by the 
prescriber keeping the individual with epilepsy and 
thecarer informed before drug therapy is started. 
When to Start AEDs after first seizures 
Whether to treat first seizure is controversial studies show 
16-62% recur within 5 years, Relapse rate is reduced by 
antiepileptic drug treatment, and it is now recommended 
that since Neurological abnormalities, abnormal imaging, 
abnormal EEG or family history increase relapse risk these 
patients should be treated after first seizure. 
(Table 4)
AED should be selected according to suitability of the 
patient, type of epilepsy etc.
Table 3 shows factors determining suitability. 
 
Table 5
The diagnosis of epilepsy needs to be critically evaluated if 
events continue despite an optimal dose of a first line AED. 
Before combination therapy is considered, PWE should be 
given a trial of at least 2-3 appropriate monotherapy 
regimens, with caution during the transition.
General Recommendations:
1)   It is recommended that PWE should be treated 
     with a single AED (monotherapy).  If the initial 
     treatment is unsuccessful, then monotherapy 
     using another drug can be tried.  
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2)   Caution is needed during the changeover period, 
     with the second drug titrated and the first drug 
     decreased gradually. 
3)   It is recommended that combination therapy 
     (adjunctive or ‘add-on’ therapy) should only be 
     considered when attempts at monotherapy with 
     AEDs have not resulted in seizure control. 
4)   If trials of combination therapy do not bring about 
     worth while benefits, Diagnosis should be revisited 
     and treatment should revert to the regimen with 
     best control providing efficacy in reducing seizures 
     and tolerability of side effects.  
5)   Refer to specialist for phase II evaluation and 
     Epilepsy surgery, classify and diagnose cause of 
     refractory epilepsy, epileptic or non-epileptic fits.
6)   If an AED has failed because of adverse effects or 
     continued seizures, a second drug should be 
     started (which may be an alternative first-line or 
     second-line drug) and built up to an adequate or 
     maximum tolerated dose and then the first drug 
     should be tapered off slowly.  
7)   If the second drug is unhelpful, either the first or 
     second drug may be tapered, depending on 
     relative efficacy, side effects and how well the 
     drugs are tolerated before starting another drug.
8)   It should be recognised that some PWEs (through 
     their families in some instances) may choose not 
     to take AED therapy following a full discussion of 
     risks and benefits. Reason should be sought and 
     addressed accordingly. Treatment should be 
     insisted upon if risk of recurrence is high as 
     described in table 3. 
9)   Treatment of a first unprovoked seizure reduces 
     the risk of recurrence in the short-term. 
     In children, treatment of a first unprovoked seizure 
     does not alter the long-term prognosis for seizure
     remission.
10) AED therapy should only be started once the 
     diagnosis of epilepsy is confirmed, except in 
     exceptional circumstances that require discussion 
     and agreement between the physician and the 
     PWE and/or carers as appropriate.   
11) Continuing AED therapy should be planned by the 
     physician. It should be part of the PWE agreed 
     treatment plan, which should include  details of 
     how  specific drug choices were made, drug 
     dosage, possible side effects, and action to take if 
     seizures persist.
12) When possible, choose which AED to offer on the 
     basis of the presenting epilepsy syndrome. If the 
     epilepsy syndrome is not clear at presentation, 
     base the decision on the presenting seizure 
     type(s). 
13) Consistent supply to the PWE of a particular
     manufacturer’s AED preparation is recommended. 
     Different preparations of some AEDs may vary in 
     bioavailability or pharmacokinetic profiles and care 
     needs to be taken to avoid reduced effect 
     orexcessive side effects. 
14) Where partial seizures are suspected prefer 
     sodium channel blockers as first line AEDs (see fig 1)
15) Where generalized seizure syndromes are susp- 
     ected consider broader spectrum AEDs (see fig 1)
16) Phenobarbitone is a broad spectrum efficacious 
     AED that is easily available in Pakistan at minimal 
     price, therefore should still be considered as first 
     line therapy where affordability is an issue as risk 
     of seizures outweigh the long term side effects. 
17) Phenobarbitone should be offered where 
     compliance due to cost is suspectected. 
18) If using carbamazepine, check LFTs.  
19) When prescribing sodium valproate to women nd 
     girls of present and future childbearing potential, 
     discuss the possible risk of malformation and 
     neurodevelopmental impairments in an unborn 
     child, particularly with high doses of this AED or 
     when using as part of  polytherapy. Vit B, folate 
     and calcium supplements should be added.
20) Lamotrigine should be administered with caution 
     and slow titration when given as monotherapy and 
     with even slower titration when combined with 
     inducers like valproate to avoid the risk of 
     idiosyncratic reactions like Steven Johnson’s 
     syndrome and toxic epidermolysis. All patients 
     should be counseled and warned to stop 
     medication and contact the physician immediately 
     if any rash appears. 
21) Levitiracetam should be given with neuropsychiat- 
     ric issues in mind and pyridoxine supplement.
22) Maintain a high level of vigilance for treatment 
     emergent adverse effects (for example, bone 
     health issues, blood dyscrasias, and neuropsychia- 
     tric issues)
23) If management is complicated, PWE should be 
     referred to specialist.   
24) The prescriber must ensure that the PWE and/or 
     carers as appropriate are fully informed about 
     treatment including action to be taken after a 
     missed dose or after a gastrointestinal upset.   
25) Regular blood test monitoring in PWE is not 
     recommended as routine, and should be done only 
     if clinically indicated or non-complance is suspect- 
     ed as below. 
     Examples of blood tests include: 
     Before surgery – clotting studies in those on 
     sodium valproate. For Patients on enzyme inducing 
     AEDs: CBC, Electrolytes, LFTs, Vit D levels, every 
     1-2 years. Test for serum amino acids, TSH and 
     urine for organic acids in all children with neonatal 
     non-infectious seizures and refractory seizures. 
26) Asymptomatic minor abnormalities in test results 
     are not necessarily an indication for changes in 
     medication.  
27) Every patient when stable should still have a 6 
     monthly follow-up to ensure compliance, and 
     review treatment plan and side effects.
28) For uncontrolled patients treatment should be 
     reviewed at regular intervals so PWE are not 
     maintained  for  long periods  on treatment that is 
     ineffective or  poorly tolerated,  when in doubt early 
     referral is more cost effective
29) Compliance can be optimized with the following:
-     Educating PWE and their families and/or carers in 
     the understanding of their condition and the 
     rationale of treatment 
-     Reducing the stigma associated with the condition 
-     Using simple medication regimens 
-     Positive relationships between healthcare 
     professionals PWE, and their family.
-     SMS bulk reminder module
 30) The risks and benefits of continuing or withdrawing 
     AED therapy should be discussed with PWE and/or 
     carers as appropriate, who have been seizure free 
     for at least 2 years At the end of the discussion, 
     they should understand their risk of seizure 
     recurrence  off treatment. This discussion should 
     take into account details of the PWE’s epilepy 
     syndrome, prognosis and life style. 
31) When AED treatment is being discontinued in PWE 
     who has been seizure free, it should be carried out 
     slowly (at least 2-3 months) and one drug should 
     be withdrawn at a time.
32) Particular care should be taken when withdrawing 
     benzodiazepines and barbiturates (may take up to 
     6 months or longer) because of the possibility of 
     drug- related withdrawal symptoms and/or seizure 
     recurrence.  
33) PWE and carer should be counseled whereby if 
     seizures recur  the last dose  reduction is reversed 
     and medical advice is sought.
Diazepam
 (DZP)
Ethosuximide*
 (ESM)
**Felbamate
Gabapentin 
 (GBT)
Lacosamide
(LCM)
Lamotrinine 
 (LTG)
Levetiracetam
 (LEV)
Lorazepam
 (LZP)
Midazalom
Oxcarbazepine
(OXC)
5-10mgs daily
250 mgs bd
300 mgs tds
200-300 mgs tds
Initially 50mgs bd
1-2mg/kg/day
25 mgs od
25 mgs alternate 
days When on 
VPA To a target 
dose of 100mgs 
BD Children 
0.5mg/kg/day
250 mgs bd
250mgs od if
Adjunctive 
therapy 
10mg/kg/day
1-2 mgs daily
10 mgs daily
Initially 300mgs 
twice daily 
2.5-5mgs
250 mgs every 
1/52
300 mgs every 
1/52
200-300 mgs 
every 1/52
Increase weekly 
by 50mg bid
25 mgs every 
week In children 
with VPA 1-5 
mg/kg/day
Without VPA 
2-10mg/kg/day
250-500 mgs 
every week
1-2 mgs
N/A
Increased 
according to 
30mgs per day
2000 mgs daily
3600 mgs daily 
In divided doses
3600 mgs daily 
In divided doses
200mgs bd or
6-9mg/kg/day
500 mgs daily
Children 
10mg/kg/day
3000 mgs daily
(1.5g bd)
20-60mg/kg/day
4 mgs daily
20 mgs
2400 daily 
In divided doses
Drowsiness 
GIT Dist.
Drowsiness
Liver Failure and 
aplastic anemia 
rare risk 1:5000
GIT Dist.
Weight Gain
Nausea, 
dizziness, 
somnolence, 
headache
#Rash
Insomnia GIT 
Dist. Headache
Tremor with VPA
Psychosis Low 
Mood GIT
Drowsiness
Dependence
Drowsiness
Encephalopathy
Neutropenia
Prolonged/cluster 
seizures
Mono/adjunctive 
for absence szs
Adjunctive for all 
Szs types which 
have failed all 
other AEDs. Used
under strict 
specialist 
supervision
Mono/adjunctive 
for partial onset 
szs +/- sec gen
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Mono/adjunctive 
for all sz types
Adjunctive for all 
sz types Rescue 
use.
For prolonged or 
clusters of all szs.
Rescue use 
Status Epilepticus
Mono/adjunctive 
for partial onset 
Szs +/- sec gen
Medication
Acetazolamie
(AZM)
Carbamazepine 
(CBZ)  
Clobazam (CBZ)
Clonazepam 
 (CLB)
Usual Starting 
Dose
250 mgs 
bd
100-200 mgs 
1-2 times daily
2-3mg/kg/day
5-10 mgs daily
0.5 mgs bd
Titrated Up or 
Down By
250mgs every 
1/52
100 mgs every 
1/52
5-10 mgs every 
1/52
0.5 mgs
Usual Maximum 
Daily Dose
1000mgs daily 
In divided doses
2000 mgs daily
In divided doses
10-20mg/kg/day
Up to 60 mgs 
daily
8 mgs daily
Common Side 
Effects
GIT Dist. 
U&E Dist
† urine output
GIT Dist.
#Rash
Hyponatremia
agranulocytosis
Drowsiness
Drowsiness
Summary 
Of Indications
Adjunctive for all 
sz types 
especially drop 
attacks
Mono/adjunctive 
therapy. Worsens 
myoclonic and 
absence seizures
Adjunctive for all 
sz type
Mono/adjunctive 
for all sz types
Phenytoin
 (PHT)  
Phenobarbitone
(PB) 
Pregabilin
Primidone*
 (PMD)  
Rufinamide*
Tiagabine* 
(TGB)
Topiramate
(TPM)
Valproate
(VPA)
5-8mg/kg/day
150-300mgs 
daily 5mg/kg/day
30 mgs daily
Initially 25mgs bd
Initially 125mgs 
at bed time
200 mgs BD daily
5mgs bd
25 mgs daily
1mg/kg/day
300 mgs bd
5mg/kg/day 
response in steps 
of up to 600mgs 
daily at weekly 
intervals
Increased 
gradually as 
necessary (with 
plasma phenytoin 
concentration 
monitoring
15 mgs every 
month
50mgs every 
1/52
Increased by 
125mgs every 3 
days to 500mgs 
daily in 2 divided 
doses (250mgs 
bd), then 
increased 
according to 
response by 250
mg s every 3 days
200 mgs every 
1/52
5-10mgs
every 1/52
25 mgs every 
1/52
100-250 mgs 
every week
5-15mg/kg/day
Usual dose is 
200-500mgs 
daily10-15mg/kg/
day
180 mgs daily
600 mgs daily
In divided doses
1500 mgs daily 
In 2 divided 
doses
1600 mgs BD 
daily
30-45mgs daily 
(doses above 30 
mgs given in 3 
divided doses)
400mgs daily 
(mono) In 2 
divided doses
800mgs 
(adjunctive) In 2 
divided doses
( 6-9 mg/kg/day)
3000 mgs daily
15mg/kg/day
Hyponatremia 
*Rash
GIT Dist.
Gingival Hypertro-
phy Hirsutism
*Rash
Drowsiness
Weight gain
Drowsiness
GIT Dist. 
Dizziness, fatigue
Diarrhoea 
Dizziness
Nervousness
Weight Loss    
Renal Calculi 
Word Finding 
Difficulties 
Pins and needles
Weight Gain
Tremor, hair loss
Liver Toxicity
Mono/adjunctive 
for all sz types 
Status Epilepticus
Mono/adjunctive 
for all sz types 
Status Epilepticus
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Adjunctive for 
Lennox – Gastaut
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Mono/adjunctive 
for all sz types
***Vigabatrin 
(VGB)
Zonisamide*
(ZNG)
infants 
10mg/kg/day 
children
500 mgs bd
20-50mg/kg/day
50 mgs daily or 
25mg bd. 
1-2mg/kg/day
Increased 
according to 
response in steps 
of 500mgs at 
weekly intervals
Increased after 7 
days to 100mgs 
daily in 2 divided 
doses then 
increased if 
necessary by 
100mgs weekly
3000 mgs daily
50-150mg/kg/day
500 mgs daily
8-12mg/kg/day
 
Teratogenecity
Hyperkinesia, 
insomnia,Visual 
field constriction 
in 30% of 
patients
Weight loss
Ataxia 
  Renal Calculi 
Adjunctive for 
partial onset szs 
+/- sec gen 
Monotherapy for 
Wests syndrome
Adjunctive for 
partial onset szs 
+/- sec gen
Table 6: List of available AED’s worldwide vs those available in Pakistan with abbreviations, dosage, indication and 
common side effects.
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
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observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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400mgs daily 
(mono) In 2 
divided doses
800mgs 
(adjunctive) In 2 
divided doses
( 6-9 mg/kg/day)
3000 mgs daily
15mg/kg/day
Hyponatremia 
*Rash
GIT Dist.
Gingival Hypertro-
phy Hirsutism
*Rash
Drowsiness
Weight gain
Drowsiness
GIT Dist. 
Dizziness, fatigue
Diarrhoea 
Dizziness
Nervousness
Weight Loss    
Renal Calculi 
Word Finding 
Difficulties 
Pins and needles
Weight Gain
Tremor, hair loss
Liver Toxicity
Mono/adjunctive 
for all sz types 
Status Epilepticus
Mono/adjunctive 
for all sz types 
Status Epilepticus
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Adjunctive for 
Lennox – Gastaut
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Mono/adjunctive 
for all sz types
***Vigabatrin 
(VGB)
Zonisamide*
(ZNG)
infants 
10mg/kg/day 
children
500 mgs bd
20-50mg/kg/day
50 mgs daily or 
25mg bd. 
1-2mg/kg/day
Increased 
according to 
response in steps 
of 500mgs at 
weekly intervals
Increased after 7 
days to 100mgs 
daily in 2 divided 
doses then 
increased if 
necessary by 
100mgs weekly
3000 mgs daily
50-150mg/kg/day
500 mgs daily
8-12mg/kg/day
 
Teratogenecity
Hyperkinesia, 
insomnia,Visual 
field constriction 
in 30% of 
patients
Weight loss
Ataxia 
  Renal Calculi 
Adjunctive for 
partial onset szs 
+/- sec gen 
Monotherapy for 
Wests syndrome
Adjunctive for 
partial onset szs 
+/- sec gen
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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Diazepam
 (DZP)
Ethosuximide*
 (ESM)
**Felbamate
Gabapentin 
 (GBT)
Lacosamide
(LCM)
Lamotrinine 
 (LTG)
Levetiracetam
 (LEV)
Lorazepam
 (LZP)
Midazalom
Oxcarbazepine
(OXC)
5-10mgs daily
250 mgs bd
300 mgs tds
200-300 mgs tds
Initially 50mgs bd
1-2mg/kg/day
25 mgs od
25 mgs alternate 
days When on 
VPA To a target 
dose of 100mgs 
BD Children 
0.5mg/kg/day
250 mgs bd
250mgs od if
Adjunctive 
therapy 
10mg/kg/day
1-2 mgs daily
10 mgs daily
Initially 300mgs 
twice daily 
2.5-5mgs
250 mgs every 
1/52
300 mgs every 
1/52
200-300 mgs 
every 1/52
Increase weekly 
by 50mg bid
25 mgs every 
week In children 
with VPA 1-5 
mg/kg/day
Without VPA 
2-10mg/kg/day
250-500 mgs 
every week
1-2 mgs
N/A
Increased 
according to 
30mgs per day
2000 mgs daily
3600 mgs daily 
In divided doses
3600 mgs daily 
In divided doses
200mgs bd or
6-9mg/kg/day
500 mgs daily
Children 
10mg/kg/day
3000 mgs daily
(1.5g bd)
20-60mg/kg/day
4 mgs daily
20 mgs
2400 daily 
In divided doses
Drowsiness 
GIT Dist.
Drowsiness
Liver Failure and 
aplastic anemia 
rare risk 1:5000
GIT Dist.
Weight Gain
Nausea, 
dizziness, 
somnolence, 
headache
#Rash
Insomnia GIT 
Dist. Headache
Tremor with VPA
Psychosis Low 
Mood GIT
Drowsiness
Dependence
Drowsiness
Encephalopathy
Neutropenia
Prolonged/cluster 
seizures
Mono/adjunctive 
for absence szs
Adjunctive for all 
Szs types which 
have failed all 
other AEDs. Used
under strict 
specialist 
supervision
Mono/adjunctive 
for partial onset 
szs +/- sec gen
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Mono/adjunctive 
for all sz types
Adjunctive for all 
sz types Rescue 
use.
For prolonged or 
clusters of all szs.
Rescue use 
Status Epilepticus
Mono/adjunctive 
for partial onset 
Szs +/- sec gen
Medication
Acetazolamie
(AZM)
Carbamazepine 
(CBZ)  
Clobazam (CBZ)
Clonazepam 
 (CLB)
Usual Starting 
Dose
250 mgs 
bd
100-200 mgs 
1-2 times daily
2-3mg/kg/day
5-10 mgs daily
0.5 mgs bd
Titrated Up or 
Down By
250mgs every 
1/52
100 mgs every 
1/52
5-10 mgs every 
1/52
0.5 mgs
Usual Maximum 
Daily Dose
1000mgs daily 
In divided doses
2000 mgs daily
In divided doses
10-20mg/kg/day
Up to 60 mgs 
daily
8 mgs daily
Common Side 
Effects
GIT Dist. 
U&E Dist
† urine output
GIT Dist.
#Rash
Hyponatremia
agranulocytosis
Drowsiness
Drowsiness
Summary 
Of Indications
Adjunctive for all 
sz types 
especially drop 
attacks
Mono/adjunctive 
therapy. Worsens 
myoclonic and 
absence seizures
Adjunctive for all 
sz type
Mono/adjunctive 
for all sz types
Phenytoin
 (PHT)  
Phenobarbitone
(PB) 
Pregabilin
Primidone*
 (PMD)  
Rufinamide*
Tiagabine* 
(TGB)
Topiramate
(TPM)
Valproate
(VPA)
5-8mg/kg/day
150-300mgs 
daily 5mg/kg/day
30 mgs daily
Initially 25mgs bd
Initially 125mgs 
at bed time
200 mgs BD daily
5mgs bd
25 mgs daily
1mg/kg/day
300 mgs bd
5mg/kg/day 
response in steps 
of up to 600mgs 
daily at weekly 
intervals
Increased 
gradually as 
necessary (with 
plasma phenytoin 
concentration 
monitoring
15 mgs every 
month
50mgs every 
1/52
Increased by 
125mgs every 3 
days to 500mgs 
daily in 2 divided 
doses (250mgs 
bd), then 
increased 
according to 
response by 250
mg s every 3 days
200 mgs every 
1/52
5-10mgs
every 1/52
25 mgs every 
1/52
100-250 mgs 
every week
5-15mg/kg/day
Usual dose is 
200-500mgs 
daily10-15mg/kg/
day
180 mgs daily
600 mgs daily
In divided doses
1500 mgs daily 
In 2 divided 
doses
1600 mgs BD 
daily
30-45mgs daily 
(doses above 30 
mgs given in 3 
divided doses)
400mgs daily 
(mono) In 2 
divided doses
800mgs 
(adjunctive) In 2 
divided doses
( 6-9 mg/kg/day)
3000 mgs daily
15mg/kg/day
Hyponatremia 
*Rash
GIT Dist.
Gingival Hypertro-
phy Hirsutism
*Rash
Drowsiness
Weight gain
Drowsiness
GIT Dist. 
Dizziness, fatigue
Diarrhoea 
Dizziness
Nervousness
Weight Loss    
Renal Calculi 
Word Finding 
Difficulties 
Pins and needles
Weight Gain
Tremor, hair loss
Liver Toxicity
Mono/adjunctive 
for all sz types 
Status Epilepticus
Mono/adjunctive 
for all sz types 
Status Epilepticus
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Adjunctive for 
Lennox – Gastaut
Adjunctive for 
partial onset szs 
+/- sec gen
Mono/adjunctive 
for all sz types
Mono/adjunctive 
for all sz types
***Vigabatrin 
(VGB)
Zonisamide*
(ZNG)
infants 
10mg/kg/day 
children
500 mgs bd
20-50mg/kg/day
50 mgs daily or 
25mg bd. 
1-2mg/kg/day
Increased 
according to 
response in steps 
of 500mgs at 
weekly intervals
Increased after 7 
days to 100mgs 
daily in 2 divided 
doses then 
increased if 
necessary by 
100mgs weekly
3000 mgs daily
50-150mg/kg/day
500 mgs daily
8-12mg/kg/day
 
Teratogenecity
Hyperkinesia, 
insomnia,Visual 
field constriction 
in 30% of 
patients
Weight loss
Ataxia 
  Renal Calculi 
Adjunctive for 
partial onset szs 
+/- sec gen 
Monotherapy for 
Wests syndrome
Adjunctive for 
partial onset szs 
+/- sec gen
Not available in Pakistan or difficult to get
**Felbamate - Patients are usually electively admitted 
when initiating this AED due to the incidence of fatal 
liver failure and aplastic anaemia, for routine lab 
observation. 
***Vigabatrinl - Its use is restricted to whom all other 
combinations are inadequate or not tolerated. It must 
only be initiated by a Neurologist. All patients must have 
visual field testing prior to commencement and every 
6/12 thereafter. 
# Rash All AEDs carry the risk of rash, however the 
drugs highlighted as Rash carry a risk of Stevens - 
Johnsons Syndrome.
• Enzyme inducers and affect the metabolism of other 
drugs, for example Oral Contraceptives; women need to 
be alerted of this interaction. 
weak enzyme inducers and may affect the metabolism 
of other drugs at high doses. 
• Signs and Symptoms of Toxicity:  vary from drug to 
drug however the following may indicate possible 
toxicity: Diplopia, blurred vision, unsteady gait, 
excessive tiredness, new onset of dizziness. 
• GIT Dist may manifest as anorexia, nausea, vomiting 
dyspepsia, constipation, diarrhoea or any s/s of GI 
disturbance Interactions between antiepileptic drugs 
are complex and may enhance toxicity without a 
corresponding increase in antiepileptic effect. 
Interactions are usually caused by hepatic enzyme 
induction or hepatic enzyme inhibition. These 
interactions are highly variable and unpredictable. 
AED INTERACTIONS
Some common interactons between antiepileptic drugs 
and non-antiepileptic drugs are listed below in table 7. 
For a full list consult the PDR Summary of Product 
Characteristics for each drug.  
Note
-     Enzyme inducing AED’s increase the rate of 
     metabolism of Warfarin and The INR should be 
     monitored carefully when an enzyme AED is added 
     or discontinued.
-     Aspirin enhances valproate and phenytoin effects. 
-     Antibiotics, macrolides (clarithromycin/erythromy- 
     cin) increase the plasma concentration of carbam- 
     azepine and inhibit the metabolism of phenytoin.  
     Erythromycin possibly inhibits the metabolism of 
     valproate.
-     Meropenam, reduces plasma concentrations of 
     valproate.
-     Rifamycins accelerate phenytoin metaboism. 
-     Analgesics, NSAIDs enhance the effects of 
     phenytoin. 
-     Estrogens, enzyme inducing drugs accelerate 
     metabolism of Estrogens reducing contraceptive 
     effects. Estrogens reduce lamotrigine levels. 
-     Plasma concentration of lamotrigine increased by 
     valproate.
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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Table 7.  Examples of important Drug interactions
Agents
Carbamazepine
Clonazepam
Divalproate Sodium, 
Valproaci acid
Phenytoin
General interactions
The simultaneous 
administration of other 
liqu- id medicines with 
CBZ suspension can 
cause rubbery precipitate 
in stool. Co- 
administration with 
lithiumcan   neurotoxic 
SE. Other AEDs may 
alter thyroid functions. 
  es efficacy of hormonal 
contraceptives.
CNS depressants, 
MAOIs, TCAs and some 
anti convulsants may 
increase depressant 
effects of CNZ.
With VPA in Absence 
seizures can induce 
absence status!
Drugs that elevate 
expression of hepatic 
enzymes increase the 
clearance of valproate. It 
increases free levels of 
warfarin
Needs caution with other 
albumin binding drugs, 
PB, VPA, have 
un-predictable effect on 
levels.Antacids with 
calcium 
inhibitsabsorption. TCAs 
  risk for Sz.
Agents that may 
increase plasma levels
CYP 3A4 inhibitors 
Propoxiphene, 
Vigabatrin, VPA, 
protriptyline, loxopine, 
sertraline, ritonavir, 
nafimidone, isoniazid, 
verapamil, ketoconazole, 
cimetidine, flunerazine, 
viloxazine, macrolides, 
diltiazem
CYP 3A inhibitors
Azole  antifungals, 
cimetidine
Asprin, felbamate, 
macrolides especially 
clarithromycin
CYP inhibitors, Azoles,, 
trimethoprim, 
chloramphenicol, 
isoniazid, disulfiram, 
phenylbutazone, 
cimetidine, SSRI, 
felbamate, TPM, CBZ, 
ranitidine, ibuprofen, 
amiodrone, diltiazem.
Agents that may 
decrease plasma 
levels
CYP 3A4 inducers, 
felbamate, PHT, 
mefloquin
CBZ
Cholestyramine, 
meropenum, CBZ, PHT, 
PB, rifampin. Primidone, 
TPM
CYP inducers, Rifampin, 
doxorubicin, VPA, 
vigabatrin.
Fig 1: Mechanisms of action of antiepileptic drugs modified from j. physiology 2006
• Laser Ablation 
Surgical Treatment 
• Upto 85% seizure-free rates
• Resections:
- lesionectomy, lobectomy, hemispherectomy
• Disconnections:
- Callosotomy, subpial transection, steriotactic 
 ablations
• Augmentations:
- Vagal, cerebellar, thalamic, deep brain stimulation
All patients with focal onset seizures that are refractory 
to an adequate trial of two or more AEDs of choice and 
are refractory to treatment should be referred for phase 
1 surgical evaluation to an epilepsy specialist. All 
lesion-related Epilepsy syndromes should be 
considered for surgical management 
SUMMARY:
These guidelines hope to highlight the problems that 
exist in the care and management of epilepsy patients 
like Patient  and physician awareness , social and 
cultural beliefs, easy access to treatment,misdiagnosis, 
inappropriate or Inadequatetreatment, sudden 
unexpected death that might have been prevented, 
preventable etiologies, Women with epilepsy, epilepsy 
in children, epilepsy in the elderly, advice about 
pregnancy and contraception and management of 
status epilepticus in children and adults. These 
guideline will be revisited and modified on applicability 
every four years and it is vital that a spotlight is kept on 
the need to further develop variable services for people 
with epilepsy. The place of newly licensed drugs, 
stigmas, and cost for epilepsy also needs careful 
consideration. The primary scope of these guidelines 
ofcourse is to provide a concise practical management 
plan which considers the role of AEDs especially their 
judicial use. The role of established and newly licensed 
drugs is considered with comparison of cost effectiveness. 
People with epilepsy remain at the centre of this 
guideline, and the need for services to consider the 
needs of each individual and their care givers have been 
focused. Attention has been paid to ensure that the 
recommendations are written in clear language and be 
accessible, and, I hope, useful to all. We remain 
committed to the care ofpeople with epilepsy and 
commend these guidelines to you in that light.
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potentially level D efficacious/effective as initial 
monotherapy for adults with newly diagnosed or 
untreated generalized onset tonic-clonic seizures. Class 
IV evidence suggests that CBZ and PHT and other 
sodium channel blockers may precipitate or aggravate 
generalized onset seizures. (ILAE updates 2013).
RECOMMENDATIONS 
1)   Offer sodium valproate as firstline treatment to 
     adults with newly diagnosed GTCs. 
     (Be aware of teratogenic risks of sodium valproate 
     in women of child bearing age)
2)   Offer lamotrigine if sodium valproate is unsuitable. 
     If the person has myoclonic seizures or is 
     suspected of having juvenile myoclonic epilepsy 
     (JME), (be aware  that lamotrigine may exacerbate 
     myoclonic seizures.  Be aware of idiosyncratic 
     reaction of lamotrigine by slow escalation) 
3)   Consider levitiracetamand Phenobarbital in 
     patients where VPA and LTG are not suitable.
4)   Offer clobazam, CBZ, OXC and TPM as adjunctive 
     treatment to adults with GTC seizures if first line 
     treatments as above are ineffective or not 
     tolerated. (Be aware of the risk of   exacerbating 
     myoclonic or absence seizures with CBZ and OXC)  
5)   If there are absence or myoclonic seizures, or if 
     JME is suspected, do not offer carbamazepine, 
     gabapentin, oxcarbazepine, phenytoin, pregabalin, 
     tiagabine or vigabatrin.
KETOGENIC DIET 
INTRODUCTION
The ketogenic diet (KD) is a high fat, low carbohydrate 
and protein diet designed to mimic the biochemical 
response of the body to starvation when ketone bodies 
become  the main fuel for the brain’s energy demands 
(Hartman 2008)It has long been used in the treatment 
of refractory epilepsy in children, although the exact 
mechanism of action is unclear. The KD diet was initially 
reported for use in epilepsy in 1921 (Wilder 1921). The 
initial diet used was the classical ketogenic diet, based 
on the ratio of fat to carbo-hydrate (with protein), of 3 
or 4:1. Later an alternative was suggested using 
triglyceride oil as a supplement, the Medium chain 
Triglyceride (MCT) Diet (Huttenlocher et al 1971). 
These diets have to be carefully administered with the 
aid of a dietician. 
•  There is no evidence of efficacy of ketogenic 
 diet in  adults.
• 50% efficacy range is achieved in children. 
• Recommended in refractory epilepsies in 
 children where multiple regimens of AEDs 
 proven ineffective.
• Local ketogenicrecipies are available and cost 
 effective.
Epilepsy Surgery 
 FDA approved surgical procedures:
• Vagus nerve stimulation
• Surgical treatment
 Investigational:
• Deep brain stimulation
• Gene therapy
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Modified from j. primary psych 2005
Initiation of AEDs Drug choice with seizure type: 
Treatment (Monotherapy) of patients with newly 
diagnosed focal (partial, complex partial and 
secondarily generalized) seizures:
A)   Adults with focal(partial) onset seizures (ILAE 2013)
RECOMMENDATIONS
1)   Offer CBZ/ OXC or PB (where cost is an issue) as 
     first line treatmentas firstline treatment to patients 
     with newlydiagnosed focal seizures.  
2)   Offer LTG,PHT, OXC or VPA if CBZ and PB are 
     unsuitable or not tolerated. If the first AED tried is
     ineffective, offer an alternative from these 5 AEDs. 
     (Be aware of the teratogenic risks of sodium 
     valproate and idiosyncratic rash of lamotrigine )
3)   Consider adjunctive treatment if a second 
     well tolerated AED is ineffective 
4)   If adjunctive treatment is ineffective or not 
     tolerated, discuss with, or refer to, an epilepsy 
     specialist or neurologist. Other AEDs that may be 
     considered by the epilepsy specialist are 
     eslicarbazepine acetate (ECA), clobazam, 
     lacosamide, phenytoin, pregabalin, tiagabine, 
     vigabatrin and zonisamide. Carefully consider the 
     risk benefit ratio when using vigabatrin because of 
     the risk of an irreversible effect on visual fields.
Pharmacological management(monotherapy) of 
Adults with newly diagnosed Generalized Epilepsy 
Syndromes (IGE).
The absence of class I and II RCTs(randomized 
controlled trials) for adults with GTC seizures implies a 
marked deficiency in published studies. No AED has 
reached the highest level of evidence (level A and B) for 
efficacy. VPA, LTG,TPM, OXC, PB, PHT, TPM, and CBZ 
are possibly level C, and GBP, LEV, and VGB are 
Table 9. Focal Seizures AED Selection guide by seizure type
Clinical Situation  Simple Partial Sz Complex Partial Sz Secondary generalized
   
Initial Monotherapy CBZ CBZ CBZ
 OXC OXC PHT
 PHT PHT OXC
 LTG LTG LTG
  LEV VPA
  ZNS LEV
   ZNS
Table 8. Medication Selection In Patients with Focal onset seizures or symptomatic lesion related Epilepsies. 
1st line AEDs 2nd Line AEDs 3rd Line AEDs
Carbamazepine CBZ Levitiracetam LEV Clonazepam CNZ
Phenytoin PHT Valproate VPA TiagabinTGN*
Oxcarbazepine OXC Topiramate TPM  EsilCarbazepine Acetate ECA*
Lamotrigine LTG Gabapentine GBP ZonisamideZNS*
Phenobarbitone PB Lacosamide LCM Perampanel*
    Clobazam CLB
    Rufinamide*
    Vigabatrin
*Not avai lable in Pakistan 
• Laser Ablation 
Surgical Treatment 
• Upto 85% seizure-free rates
• Resections:
- lesionectomy, lobectomy, hemispherectomy
• Disconnections:
- Callosotomy, subpial transection, steriotactic 
 ablations
• Augmentations:
- Vagal, cerebellar, thalamic, deep brain stimulation
All patients with focal onset seizures that are refractory 
to an adequate trial of two or more AEDs of choice and 
are refractory to treatment should be referred for phase 
1 surgical evaluation to an epilepsy specialist. All 
lesion-related Epilepsy syndromes should be 
considered for surgical management 
SUMMARY:
These guidelines hope to highlight the problems that 
exist in the care and management of epilepsy patients 
like Patient  and physician awareness , social and 
cultural beliefs, easy access to treatment,misdiagnosis, 
inappropriate or Inadequatetreatment, sudden 
unexpected death that might have been prevented, 
preventable etiologies, Women with epilepsy, epilepsy 
in children, epilepsy in the elderly, advice about 
pregnancy and contraception and management of 
status epilepticus in children and adults. These 
guideline will be revisited and modified on applicability 
every four years and it is vital that a spotlight is kept on 
the need to further develop variable services for people 
with epilepsy. The place of newly licensed drugs, 
stigmas, and cost for epilepsy also needs careful 
consideration. The primary scope of these guidelines 
ofcourse is to provide a concise practical management 
plan which considers the role of AEDs especially their 
judicial use. The role of established and newly licensed 
drugs is considered with comparison of cost effectiveness. 
People with epilepsy remain at the centre of this 
guideline, and the need for services to consider the 
needs of each individual and their care givers have been 
focused. Attention has been paid to ensure that the 
recommendations are written in clear language and be 
accessible, and, I hope, useful to all. We remain 
committed to the care ofpeople with epilepsy and 
commend these guidelines to you in that light.
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potentially level D efficacious/effective as initial 
monotherapy for adults with newly diagnosed or 
untreated generalized onset tonic-clonic seizures. Class 
IV evidence suggests that CBZ and PHT and other 
sodium channel blockers may precipitate or aggravate 
generalized onset seizures. (ILAE updates 2013).
RECOMMENDATIONS 
1)   Offer sodium valproate as firstline treatment to 
     adults with newly diagnosed GTCs. 
     (Be aware of teratogenic risks of sodium valproate 
     in women of child bearing age)
2)   Offer lamotrigine if sodium valproate is unsuitable. 
     If the person has myoclonic seizures or is 
     suspected of having juvenile myoclonic epilepsy 
     (JME), (be aware  that lamotrigine may exacerbate 
     myoclonic seizures.  Be aware of idiosyncratic 
     reaction of lamotrigine by slow escalation) 
3)   Consider levitiracetamand Phenobarbital in 
     patients where VPA and LTG are not suitable.
4)   Offer clobazam, CBZ, OXC and TPM as adjunctive 
     treatment to adults with GTC seizures if first line 
     treatments as above are ineffective or not 
     tolerated. (Be aware of the risk of   exacerbating 
     myoclonic or absence seizures with CBZ and OXC)  
5)   If there are absence or myoclonic seizures, or if 
     JME is suspected, do not offer carbamazepine, 
     gabapentin, oxcarbazepine, phenytoin, pregabalin, 
     tiagabine or vigabatrin.
KETOGENIC DIET 
INTRODUCTION
The ketogenic diet (KD) is a high fat, low carbohydrate 
and protein diet designed to mimic the biochemical 
response of the body to starvation when ketone bodies 
become  the main fuel for the brain’s energy demands 
(Hartman 2008)It has long been used in the treatment 
of refractory epilepsy in children, although the exact 
mechanism of action is unclear. The KD diet was initially 
reported for use in epilepsy in 1921 (Wilder 1921). The 
initial diet used was the classical ketogenic diet, based 
on the ratio of fat to carbo-hydrate (with protein), of 3 
or 4:1. Later an alternative was suggested using 
triglyceride oil as a supplement, the Medium chain 
Triglyceride (MCT) Diet (Huttenlocher et al 1971). 
These diets have to be carefully administered with the 
aid of a dietician. 
•  There is no evidence of efficacy of ketogenic 
 diet in  adults.
• 50% efficacy range is achieved in children. 
• Recommended in refractory epilepsies in 
 children where multiple regimens of AEDs 
 proven ineffective.
• Local ketogenicrecipies are available and cost 
 effective.
Epilepsy Surgery 
 FDA approved surgical procedures:
• Vagus nerve stimulation
• Surgical treatment
 Investigational:
• Deep brain stimulation
• Gene therapy
Pharmacological management(monotherapy) of 
Adults with newly diagnosed Generalized Epilepsy 
Syndromes (IGE).
The absence of class I and II RCTs(randomized 
controlled trials) for adults with GTC seizures implies a 
marked deficiency in published studies. No AED has 
reached the highest level of evidence (level A and B) for 
efficacy. VPA, LTG,TPM, OXC, PB, PHT, TPM, and CBZ 
are possibly level C, and GBP, LEV, and VGB are 
Table 10: Generalized Tonic Clonic Epilepsy – AEDs of choice 
#Avoid in myoclonus *not available in Pakistan 
Table 11. Idiopathic Generalized Epilepsy: 
Medication Selection 
1st line  2nd line  3rd line 
  
VPA TPM CNZ
LTG# ZNS* CBM
TPM LEV GBP
LEV PB CBZ#
 PHT# OXC#
  VIGABATRIN
  ETHOSUXIMIDE
AED selection           Clinical situation
 GTC Absence Myoclonic
Initial LPA VPA VPA 
monotherapy LTG ESM LEV
2nd  LTG ESM LEV
Monotherapy LEV LTG TPM
if VPA failed  
2nd TPM LEV TPM
Monotherapy LEV VPA LEV
if LTG/LEV failed LTG ESM VPA 
 ZNS ZNS ZNS
  LTG
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• Laser Ablation 
Surgical Treatment 
• Upto 85% seizure-free rates
• Resections:
- lesionectomy, lobectomy, hemispherectomy
• Disconnections:
- Callosotomy, subpial transection, steriotactic 
 ablations
• Augmentations:
- Vagal, cerebellar, thalamic, deep brain stimulation
All patients with focal onset seizures that are refractory 
to an adequate trial of two or more AEDs of choice and 
are refractory to treatment should be referred for phase 
1 surgical evaluation to an epilepsy specialist. All 
lesion-related Epilepsy syndromes should be 
considered for surgical management 
SUMMARY:
These guidelines hope to highlight the problems that 
exist in the care and management of epilepsy patients 
like Patient  and physician awareness , social and 
cultural beliefs, easy access to treatment,misdiagnosis, 
inappropriate or Inadequatetreatment, sudden 
unexpected death that might have been prevented, 
preventable etiologies, Women with epilepsy, epilepsy 
in children, epilepsy in the elderly, advice about 
pregnancy and contraception and management of 
status epilepticus in children and adults. These 
guideline will be revisited and modified on applicability 
every four years and it is vital that a spotlight is kept on 
the need to further develop variable services for people 
with epilepsy. The place of newly licensed drugs, 
stigmas, and cost for epilepsy also needs careful 
consideration. The primary scope of these guidelines 
ofcourse is to provide a concise practical management 
plan which considers the role of AEDs especially their 
judicial use. The role of established and newly licensed 
drugs is considered with comparison of cost effectiveness. 
People with epilepsy remain at the centre of this 
guideline, and the need for services to consider the 
needs of each individual and their care givers have been 
focused. Attention has been paid to ensure that the 
recommendations are written in clear language and be 
accessible, and, I hope, useful to all. We remain 
committed to the care ofpeople with epilepsy and 
commend these guidelines to you in that light.
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potentially level D efficacious/effective as initial 
monotherapy for adults with newly diagnosed or 
untreated generalized onset tonic-clonic seizures. Class 
IV evidence suggests that CBZ and PHT and other 
sodium channel blockers may precipitate or aggravate 
generalized onset seizures. (ILAE updates 2013).
RECOMMENDATIONS 
1)   Offer sodium valproate as firstline treatment to 
     adults with newly diagnosed GTCs. 
     (Be aware of teratogenic risks of sodium valproate 
     in women of child bearing age)
2)   Offer lamotrigine if sodium valproate is unsuitable. 
     If the person has myoclonic seizures or is 
     suspected of having juvenile myoclonic epilepsy 
     (JME), (be aware  that lamotrigine may exacerbate 
     myoclonic seizures.  Be aware of idiosyncratic 
     reaction of lamotrigine by slow escalation) 
3)   Consider levitiracetamand Phenobarbital in 
     patients where VPA and LTG are not suitable.
4)   Offer clobazam, CBZ, OXC and TPM as adjunctive 
     treatment to adults with GTC seizures if first line 
     treatments as above are ineffective or not 
     tolerated. (Be aware of the risk of   exacerbating 
     myoclonic or absence seizures with CBZ and OXC)  
5)   If there are absence or myoclonic seizures, or if 
     JME is suspected, do not offer carbamazepine, 
     gabapentin, oxcarbazepine, phenytoin, pregabalin, 
     tiagabine or vigabatrin.
KETOGENIC DIET 
INTRODUCTION
The ketogenic diet (KD) is a high fat, low carbohydrate 
and protein diet designed to mimic the biochemical 
response of the body to starvation when ketone bodies 
become  the main fuel for the brain’s energy demands 
(Hartman 2008)It has long been used in the treatment 
of refractory epilepsy in children, although the exact 
mechanism of action is unclear. The KD diet was initially 
reported for use in epilepsy in 1921 (Wilder 1921). The 
initial diet used was the classical ketogenic diet, based 
on the ratio of fat to carbo-hydrate (with protein), of 3 
or 4:1. Later an alternative was suggested using 
triglyceride oil as a supplement, the Medium chain 
Triglyceride (MCT) Diet (Huttenlocher et al 1971). 
These diets have to be carefully administered with the 
aid of a dietician. 
•  There is no evidence of efficacy of ketogenic 
 diet in  adults.
• 50% efficacy range is achieved in children. 
• Recommended in refractory epilepsies in 
 children where multiple regimens of AEDs 
 proven ineffective.
• Local ketogenicrecipies are available and cost 
 effective.
Epilepsy Surgery 
 FDA approved surgical procedures:
• Vagus nerve stimulation
• Surgical treatment
 Investigational:
• Deep brain stimulation
• Gene therapy
Pharmacological management(monotherapy) of 
Adults with newly diagnosed Generalized Epilepsy 
Syndromes (IGE).
The absence of class I and II RCTs(randomized 
controlled trials) for adults with GTC seizures implies a 
marked deficiency in published studies. No AED has 
reached the highest level of evidence (level A and B) for 
efficacy. VPA, LTG,TPM, OXC, PB, PHT, TPM, and CBZ 
are possibly level C, and GBP, LEV, and VGB are 
6 1 V O L .  1 0  ( 3 )  J U L   -   S E P T   2 0 1 5P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
• Laser Ablation 
Surgical Treatment 
• Upto 85% seizure-free rates
• Resections:
- lesionectomy, lobectomy, hemispherectomy
• Disconnections:
- Callosotomy, subpial transection, steriotactic 
 ablations
• Augmentations:
- Vagal, cerebellar, thalamic, deep brain stimulation
All patients with focal onset seizures that are refractory 
to an adequate trial of two or more AEDs of choice and 
are refractory to treatment should be referred for phase 
1 surgical evaluation to an epilepsy specialist. All 
lesion-related Epilepsy syndromes should be 
considered for surgical management 
SUMMARY:
These guidelines hope to highlight the problems that 
exist in the care and management of epilepsy patients 
like Patient  and physician awareness , social and 
cultural beliefs, easy access to treatment,misdiagnosis, 
inappropriate or Inadequatetreatment, sudden 
unexpected death that might have been prevented, 
preventable etiologies, Women with epilepsy, epilepsy 
in children, epilepsy in the elderly, advice about 
pregnancy and contraception and management of 
status epilepticus in children and adults. These 
guideline will be revisited and modified on applicability 
every four years and it is vital that a spotlight is kept on 
the need to further develop variable services for people 
with epilepsy. The place of newly licensed drugs, 
stigmas, and cost for epilepsy also needs careful 
consideration. The primary scope of these guidelines 
ofcourse is to provide a concise practical management 
plan which considers the role of AEDs especially their 
judicial use. The role of established and newly licensed 
drugs is considered with comparison of cost effectiveness. 
People with epilepsy remain at the centre of this 
guideline, and the need for services to consider the 
needs of each individual and their care givers have been 
focused. Attention has been paid to ensure that the 
recommendations are written in clear language and be 
accessible, and, I hope, useful to all. We remain 
committed to the care ofpeople with epilepsy and 
commend these guidelines to you in that light.
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potentially level D efficacious/effective as initial 
monotherapy for adults with newly diagnosed or 
untreated generalized onset tonic-clonic seizures. Class 
IV evidence suggests that CBZ and PHT and other 
sodium channel blockers may precipitate or aggravate 
generalized onset seizures. (ILAE updates 2013).
RECOMMENDATIONS 
1)   Offer sodium valproate as firstline treatment to 
     adults with newly diagnosed GTCs. 
     (Be aware of teratogenic risks of sodium valproate 
     in women of child bearing age)
2)   Offer lamotrigine if sodium valproate is unsuitable. 
     If the person has myoclonic seizures or is 
     suspected of having juvenile myoclonic epilepsy 
     (JME), (be aware  that lamotrigine may exacerbate 
     myoclonic seizures.  Be aware of idiosyncratic 
     reaction of lamotrigine by slow escalation) 
3)   Consider levitiracetamand Phenobarbital in 
     patients where VPA and LTG are not suitable.
4)   Offer clobazam, CBZ, OXC and TPM as adjunctive 
     treatment to adults with GTC seizures if first line 
     treatments as above are ineffective or not 
     tolerated. (Be aware of the risk of   exacerbating 
     myoclonic or absence seizures with CBZ and OXC)  
5)   If there are absence or myoclonic seizures, or if 
     JME is suspected, do not offer carbamazepine, 
     gabapentin, oxcarbazepine, phenytoin, pregabalin, 
     tiagabine or vigabatrin.
KETOGENIC DIET 
INTRODUCTION
The ketogenic diet (KD) is a high fat, low carbohydrate 
and protein diet designed to mimic the biochemical 
response of the body to starvation when ketone bodies 
become  the main fuel for the brain’s energy demands 
(Hartman 2008)It has long been used in the treatment 
of refractory epilepsy in children, although the exact 
mechanism of action is unclear. The KD diet was initially 
reported for use in epilepsy in 1921 (Wilder 1921). The 
initial diet used was the classical ketogenic diet, based 
on the ratio of fat to carbo-hydrate (with protein), of 3 
or 4:1. Later an alternative was suggested using 
triglyceride oil as a supplement, the Medium chain 
Triglyceride (MCT) Diet (Huttenlocher et al 1971). 
These diets have to be carefully administered with the 
aid of a dietician. 
•  There is no evidence of efficacy of ketogenic 
 diet in  adults.
• 50% efficacy range is achieved in children. 
• Recommended in refractory epilepsies in 
 children where multiple regimens of AEDs 
 proven ineffective.
• Local ketogenicrecipies are available and cost 
 effective.
Epilepsy Surgery 
 FDA approved surgical procedures:
• Vagus nerve stimulation
• Surgical treatment
 Investigational:
• Deep brain stimulation
• Gene therapy
Pharmacological management(monotherapy) of 
Adults with newly diagnosed Generalized Epilepsy 
Syndromes (IGE).
The absence of class I and II RCTs(randomized 
controlled trials) for adults with GTC seizures implies a 
marked deficiency in published studies. No AED has 
reached the highest level of evidence (level A and B) for 
efficacy. VPA, LTG,TPM, OXC, PB, PHT, TPM, and CBZ 
are possibly level C, and GBP, LEV, and VGB are 
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• Laser Ablation 
Surgical Treatment 
• Upto 85% seizure-free rates
• Resections:
- lesionectomy, lobectomy, hemispherectomy
• Disconnections:
- Callosotomy, subpial transection, steriotactic 
 ablations
• Augmentations:
- Vagal, cerebellar, thalamic, deep brain stimulation
All patients with focal onset seizures that are refractory 
to an adequate trial of two or more AEDs of choice and 
are refractory to treatment should be referred for phase 
1 surgical evaluation to an epilepsy specialist. All 
lesion-related Epilepsy syndromes should be 
considered for surgical management 
SUMMARY:
These guidelines hope to highlight the problems that 
exist in the care and management of epilepsy patients 
like Patient  and physician awareness , social and 
cultural beliefs, easy access to treatment,misdiagnosis, 
inappropriate or Inadequatetreatment, sudden 
unexpected death that might have been prevented, 
preventable etiologies, Women with epilepsy, epilepsy 
in children, epilepsy in the elderly, advice about 
pregnancy and contraception and management of 
status epilepticus in children and adults. These 
guideline will be revisited and modified on applicability 
every four years and it is vital that a spotlight is kept on 
the need to further develop variable services for people 
with epilepsy. The place of newly licensed drugs, 
stigmas, and cost for epilepsy also needs careful 
consideration. The primary scope of these guidelines 
ofcourse is to provide a concise practical management 
plan which considers the role of AEDs especially their 
judicial use. The role of established and newly licensed 
drugs is considered with comparison of cost effectiveness. 
People with epilepsy remain at the centre of this 
guideline, and the need for services to consider the 
needs of each individual and their care givers have been 
focused. Attention has been paid to ensure that the 
recommendations are written in clear language and be 
accessible, and, I hope, useful to all. We remain 
committed to the care ofpeople with epilepsy and 
commend these guidelines to you in that light.
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potentially level D efficacious/effective as initial 
monotherapy for adults with newly diagnosed or 
untreated generalized onset tonic-clonic seizures. Class 
IV evidence suggests that CBZ and PHT and other 
sodium channel blockers may precipitate or aggravate 
generalized onset seizures. (ILAE updates 2013).
RECOMMENDATIONS 
1)   Offer sodium valproate as firstline treatment to 
     adults with newly diagnosed GTCs. 
     (Be aware of teratogenic risks of sodium valproate 
     in women of child bearing age)
2)   Offer lamotrigine if sodium valproate is unsuitable. 
     If the person has myoclonic seizures or is 
     suspected of having juvenile myoclonic epilepsy 
     (JME), (be aware  that lamotrigine may exacerbate 
     myoclonic seizures.  Be aware of idiosyncratic 
     reaction of lamotrigine by slow escalation) 
3)   Consider levitiracetamand Phenobarbital in 
     patients where VPA and LTG are not suitable.
4)   Offer clobazam, CBZ, OXC and TPM as adjunctive 
     treatment to adults with GTC seizures if first line 
     treatments as above are ineffective or not 
     tolerated. (Be aware of the risk of   exacerbating 
     myoclonic or absence seizures with CBZ and OXC)  
5)   If there are absence or myoclonic seizures, or if 
     JME is suspected, do not offer carbamazepine, 
     gabapentin, oxcarbazepine, phenytoin, pregabalin, 
     tiagabine or vigabatrin.
KETOGENIC DIET 
INTRODUCTION
The ketogenic diet (KD) is a high fat, low carbohydrate 
and protein diet designed to mimic the biochemical 
response of the body to starvation when ketone bodies 
become  the main fuel for the brain’s energy demands 
(Hartman 2008)It has long been used in the treatment 
of refractory epilepsy in children, although the exact 
mechanism of action is unclear. The KD diet was initially 
reported for use in epilepsy in 1921 (Wilder 1921). The 
initial diet used was the classical ketogenic diet, based 
on the ratio of fat to carbo-hydrate (with protein), of 3 
or 4:1. Later an alternative was suggested using 
triglyceride oil as a supplement, the Medium chain 
Triglyceride (MCT) Diet (Huttenlocher et al 1971). 
These diets have to be carefully administered with the 
aid of a dietician. 
•  There is no evidence of efficacy of ketogenic 
 diet in  adults.
• 50% efficacy range is achieved in children. 
• Recommended in refractory epilepsies in 
 children where multiple regimens of AEDs 
 proven ineffective.
• Local ketogenicrecipies are available and cost 
 effective.
Epilepsy Surgery 
 FDA approved surgical procedures:
• Vagus nerve stimulation
• Surgical treatment
 Investigational:
• Deep brain stimulation
• Gene therapy
Pharmacological management(monotherapy) of 
Adults with newly diagnosed Generalized Epilepsy 
Syndromes (IGE).
The absence of class I and II RCTs(randomized 
controlled trials) for adults with GTC seizures implies a 
marked deficiency in published studies. No AED has 
reached the highest level of evidence (level A and B) for 
efficacy. VPA, LTG,TPM, OXC, PB, PHT, TPM, and CBZ 
are possibly level C, and GBP, LEV, and VGB are 
